This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Jun 11;172(11):835-6.

doi: 10.1001/archinternmed.2012.1226.

The dilemma of prostate-specific antigen testing

Robin Leach, Ian M Thompson

PMID: 22905350
PMCID: PMC5020903
DOI: 10.1001/archinternmed.2012.1226

Editorial

The dilemma of prostate-specific antigen testing

Robin Leach et al. Arch Intern Med. 2012.

. 2012 Jun 11;172(11):835-6.

doi: 10.1001/archinternmed.2012.1226.

Authors

Robin Leach, Ian M Thompson

PMID: 22905350
PMCID: PMC5020903
DOI: 10.1001/archinternmed.2012.1226

No abstract available

PubMed Disclaimer

Similar articles

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM. Tomlins SA, et al. Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16. Eur Urol. 2016. PMID: 25985884 Free PMC article.
Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P, Steurer S, Huland H, Graefen M. Schriefer P, et al. J Clin Oncol. 2012 Nov 10;30(32):e341-4. doi: 10.1200/JCO.2012.43.1767. Epub 2012 Oct 1. J Clin Oncol. 2012. PMID: 23032622 No abstract available.
Diagnostic challenges of clonal heterogeneity in prostate cancer.
Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB. Haffner MC, et al. J Clin Oncol. 2015 Mar 1;33(7):e38-40. doi: 10.1200/JCO.2013.50.3540. Epub 2014 Mar 17. J Clin Oncol. 2015. PMID: 24638011 No abstract available.
Prostate cancer: measuring PSA.
Pezaro C, Woo HH, Davis ID. Pezaro C, et al. Intern Med J. 2014 May;44(5):433-40. doi: 10.1111/imj.12407. Intern Med J. 2014. PMID: 24816306 Review.
[New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL. Kovács GL. Magy Onkol. 2014 Dec;58(4):301-9. Epub 2014 Oct 1. Magy Onkol. 2014. PMID: 25517448 Review. Hungarian.

See all similar articles

Cited by

Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.
Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, Brooks J, Watson MT, Lance RS, Troyer DA, Semmes OJ, Mehta A, Drake RR. Nyalwidhe JO, et al. Proteomics Clin Appl. 2013 Oct;7(9-10):677-89. doi: 10.1002/prca.201200134. Epub 2013 Sep 13. Proteomics Clin Appl. 2013. PMID: 23775902 Free PMC article.
Cancer incidence among capacitor manufacturing workers exposed to polychlorinated biphenyls.
Ruder AM, Hein MJ, Hopf NB, Waters MA. Ruder AM, et al. Am J Ind Med. 2017 Feb;60(2):198-207. doi: 10.1002/ajim.22657. Epub 2017 Jan 6. Am J Ind Med. 2017. PMID: 28059454 Free PMC article.

References

1. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821–827. - PubMed
1. Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010;75(2):407–413. - PMC - PubMed
1. Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology. 2011;77(4):910–914. - PubMed
1. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962. - PMC - PubMed
1. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529–534. - PubMed

Publication types

Actions
Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information